Inpharma 1307 - 29 Sep 2001

■ ‘METVAN exhibited significant antitumor activityand delayed tumor progression’ in mice, report US-based researchers. They studied severe combinedimmunodeficient mice inoculated with humanglioblastoma or breast cancer cells. Starting the dayafter inoculation, mice were given intraperitonealMETVAN 10 mg/kg or vehicle (controls), once daily on5 days per week for 4 weeks. 40 days afterinoculation, the average tumour size was significantlysmaller in METVAN recipients, compared withcontrols, among mice bearing glioblastoma cells (1688vs 4560mm3) and those bearing breast cancer cells(174 vs 487mm3). Measurable tumours developedwithin 7 days in 90–100% of control mice; in contrast,40–50% of METVAN-treated mice remained alive andfree of detectable tumours for > 16–19 days.Narla RK, et al. In vivo antitumor activity ofbis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) {METVAN[VO(SO4)(Me2-Phen)2]}. Clinical cancer research: an official journal of theAmerican Association for Cancer Research 7: 2124-2133, Jul2001 800878814

1

Inpharma 29 Sep 2001 No. 13071173-8324/10/1307-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved